Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

YTYun Kyoung TigerRARoshan AsraniANAdrienne Nedved

Discussion

Loading...

Member takes

Overview

Multicenter retrospective analysis reports 78% objective response rate for glofitamab plus gemcitabine in patients with aggressive B-cell lymphoma, suggesting strong real-world efficacy.

Key Points

  • 78% objective response rate observed among 27 evaluable patients treated with Glofitamab-GemOx for aggressive B-cell lymphoma, showing significant efficacy.
  • Medications included glofitamab, a bispecific antibody targeting CD20/CD3, combined with gemcitabine and oxaliplatin.
  • Analysis conducted at 8 U.S. academic centers assessing real-world outcomes in patients outside clinical trials.
  • Cytokine Release Syndrome was observed in 58% of patients, indicating potential toxicity concerns with this treatment regimen.

Cite This Study

Tiger et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5aahttps://doi.org/10.1182/blood-2025-1956
View Full Paper
Ask AI
Bookmark
Share